Person: Yan, Jing
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
First Name
Name
Search Results
Publication Author Correction: Towards an arthritis flare-responsive drug delivery system
(Nature Publishing Group UK, 2018) Joshi, Nitin; Yan, Jing; Levy, Seth; Bhagchandani, Sachin; Slaughter, Kai V.; Sherman, Nicholas E.; Amirault, Julian; Wang, Yufeng; Riegel, Logan; He, Xueyin; Rui, Tan Shi; Valic, Michael; Vemula, Praveen; Miranda, Oscar R.; Levy, Oren; Gravallese, Ellen M.; Aliprantis, Antonios; Ermann, Joerg; Karp, JeffreyPublication Towards an arthritis flare-responsive drug delivery system
(Nature Publishing Group UK, 2018) Joshi, Nitin; Yan, Jing; Levy, Seth; Bhagchandani, Sachin; Slaughter, Kai V.; Sherman, Nicholas E.; Amirault, Julian; Wang, Yufeng; Riegel, Logan; He, Xueyin; Rui, Tan Shi; Valic, Michael; Vemula, Praveen; Miranda, Oscar R.; Levy, Oren; Gravallese, Ellen M.; Aliprantis, Antonios; Ermann, Joerg; Karp, JeffreyLocal delivery of therapeutics for the treatment of inflammatory arthritis (IA) is limited by short intra-articular half-lives. Since IA severity often fluctuates over time, a local drug delivery method that titrates drug release to arthritis activity would represent an attractive paradigm in IA therapy. Here we report the development of a hydrogel platform that exhibits disassembly and drug release controlled by the concentration of enzymes expressed during arthritis flares. In vitro, hydrogel loaded with triamcinolone acetonide (TA) releases drug on-demand upon exposure to enzymes or synovial fluid from patients with rheumatoid arthritis. In arthritic mice, hydrogel loaded with a fluorescent dye demonstrates flare-dependent disassembly measured as loss of fluorescence. Moreover, a single dose of TA-loaded hydrogel but not the equivalent dose of locally injected free TA reduces arthritis activity in the injected paw. Together, our data suggest flare-responsive hydrogel as a promising next-generation drug delivery approach for the treatment of IA.
Publication Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation
(Nature Publishing Group UK, 2018) Carey, Heather A.; Hildreth, Blake E.; Geisler, Jennifer A.; Nickel, Mara C.; Cabrera, Jennifer; Ghosh, Sankha; Jiang, Yue; Yan, Jing; Lee, James; Makam, Sandeep; Young, Nicholas A.; Valiente, Giancarlo R.; Jarjour, Wael N.; Huang, Kun; Rosol, Thomas J.; Toribio, Ramiro E.; Charles, Julia; Ostrowski, Michael C.; Sharma, Sudarshana M.Genome-wide association studies (GWASs) have been instrumental in understanding complex phenotypic traits. However, they have rarely been used to understand lineage-specific pathways and functions that contribute to the trait. In this study, by integrating lineage-specific enhancers from mesenchymal and myeloid compartments with bone mineral density loci, we were able to segregate osteoblast- and osteoclast (OC)-specific functions. Specifically, in OCs, a PU.1-dependent transcription factor (TF) network was revealed. Deletion of PU.1 in OCs in mice resulted in severe osteopetrosis. Functional genomic analysis indicated PU.1 and MITF orchestrated a TF network essential for OC differentiation. Several of these TFs were regulated by cooperative binding of PU.1 with BRD4 to form superenhancers. Further, PU.1 is essential for conformational changes in the superenhancer region of Nfatc1. In summary, our study demonstrates that combining GWASs with genome-wide binding studies and model organisms could decipher lineage-specific pathways contributing to complex disease states.